Pioneer and expert in blood and tissue microbiota, Vaiomer carries out microbiota studies, in the fields of human and animal health, for preclinical and clinical research, CROs, dermocosmetics, nutraceuticals and pharmaceutical / biotech companies. We perform microbiota studies from a very wide variety of biological samples (blood, adipose tissue, biopsies, tumors, and more classically skin, saliva, faeces, etc.): DNA extraction, quantification by qPCR, sequencing metagenomics, Bioinformatics, Biostatistics. Upstream and downstream of the studies: support for the experimental design and the drafting of study protocols, then for the interpretation and valuation of the results. The role of tissue and blood microbiomes in systemic inflammation is studied in a wide variety of pathologies: https://vaiomer.com/microbiome-applications/ Microbiota can interact with compounds. The study of the action of a compound on the microbiota makes it possible to characterize the modulating, protective or toxic effects of the microbiota on the compound, or of the compound on the microbiota. Taking into account variations in the microbiota also makes it possible to derisk the translation from the animal model to humans: it is a new source of biomarkers of the therapeutic response (responders / non-responders). We are an expert multidisciplinary team (Scientific / Microbiota, Molecular Biology, Bioinformatics and Biostatistics), have a unique technology for samples of low bacterial biomass and a molecular biology laboratory that can process samples from infected subjects (COVID , HIV...)
